Servier Bio-innovation Llc
Clinical trials sponsored by Servier Bio-innovation Llc, explained in plain language.
-
New hope for rare bone cancer: targeted pill slows tumor growth in phase 3 trial
Disease control Recruiting nowThis study tests an oral drug called ivosidenib in people with advanced or spreading conventional chondrosarcoma, a rare bone cancer that has an IDH1 gene mutation. Participants are randomly assigned to receive either the drug or a placebo daily. The main goal is to see if the dr…
Phase: PHASE3 • Sponsor: Servier Bio-Innovation LLC • Aim: Disease control
Last updated May 26, 2026 08:54 UTC
-
New hope for cancer patients with organ issues?
Disease control Recruiting nowThis study tests an oral drug called ivosidenib in 30 adults with IDH1-mutated cancers who also have liver or kidney problems. The goal is to see how the drug behaves in the body and if it is safe. Participants take the drug daily in 28-day cycles and have regular blood tests and…
Phase: PHASE1 • Sponsor: Servier Bio-Innovation LLC • Aim: Disease control
Last updated May 26, 2026 08:32 UTC
-
New hope for Hard-to-Treat cancers: targeted drug combo enters human trials
Disease control Recruiting nowThis study tests a new oral drug, S095035, alone or with another drug (TNG462), in adults with advanced solid tumors that have a specific genetic deletion (MTAP). The goal is to see if the drug is safe and shrinks tumors. About 342 participants who have tried at least one prior t…
Phase: PHASE1, PHASE2 • Sponsor: Servier Bio-Innovation LLC • Aim: Disease control
Last updated May 22, 2026 14:04 UTC